BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 26865350)

  • 1. Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease.
    Kawakita T; Uchino M; Fukagawa K; Yoshino K; Shimazaki S; Toda I; Tanaka M; Arai H; Sakatani K; Hata S; Okano T; Tsubota K
    Sci Rep; 2016 Feb; 6():20855. PubMed ID: 26865350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
    Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
    Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation.
    Davitt WF; Bloomenstein M; Christensen M; Martin AE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):347-53. PubMed ID: 20653478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
    Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
    Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of retinoic acid ophthalmic emulsion in dry eye.
    Selek H; Unlü N; Orhan M; Irkeç M
    Eur J Ophthalmol; 2000; 10(2):121-7. PubMed ID: 10887922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
    Sosne G; Dunn SP; Kim C
    Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome.
    Sullivan LJ; McCurrach F; Lee S; Taylor HR; Rolando M; Marechal-Courtois C; Creuzot-Garcher C; Easty DL; Karabatsas C; Bingh Hoh M; Faschinger C; Laroche L
    Ophthalmology; 1997 Sep; 104(9):1402-8. PubMed ID: 9307633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board.
    Nakamura S; Shibuya M; Nakashima H; Imagawa T; Uehara M; Tsubota K
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2379-87. PubMed ID: 15980225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the clinical course of dry eye syndrome.
    Horwath-Winter J; Berghold A; Schmut O; Floegel I; Solhdju V; Bodner E; Schwantzer G; Haller-Schober EM
    Arch Ophthalmol; 2003 Oct; 121(10):1364-8. PubMed ID: 14557170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
    Hwang HS; Sung YM; Lee WS; Kim EC
    Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
    Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
    Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the mineral oil and hyaluronic acid mixture eye drops in murine dry eye.
    Choi JH; Kim JH; Li Z; Oh HJ; Ahn KY; Yoon KC
    Korean J Ophthalmol; 2015 Apr; 29(2):131-7. PubMed ID: 25829831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
    Brzheskiy VV; Efimova EL; Vorontsova TN; Alekseev VN; Gusarevich OG; Shaidurova KN; Ryabtseva AA; Andryukhina OM; Kamenskikh TG; Sumarokova ES; Miljudin ES; Egorov EA; Lebedev OI; Surov AV; Korol AR; Nasinnyk IO; Bezditko PA; Muzhychuk OP; Vygodin VA; Yani EV; Savchenko AY; Karger EM; Fedorkin ON; Mironov AN; Ostapenko V; Popeko NA; Skulachev VP; Skulachev MV
    Adv Ther; 2015 Dec; 32(12):1263-79. PubMed ID: 26660938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trehalose versus hyaluronan or cellulose in eyedrops for the treatment of dry eye.
    Matsuo T
    Jpn J Ophthalmol; 2004; 48(4):321-7. PubMed ID: 15295655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
    Demiryay E; Yaylali V; Cetin EN; Yildirim C
    Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.